Healthcare Services

Non-Cystic Fibrosis Bronchiectasis Market Forecast 2026–2035 Reflecting Expansion Opportunities Across Industries

April 3, 2026April 3, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Non-Cystic Fibrosis Bronchiectasis Market Across 2026–2030?

The non-cystic fibrosis bronchiectasis market size has experienced significant growth in recent years. Its expansion is expected to take it from $3.7 billion in 2025 to $3.93 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.4%. The factors contributing to its historical growth include recurring respiratory infections, limited public understanding of non-CF bronchiectasis, a dependence on traditional diagnostic techniques, insufficient hospital infrastructure, and the slow uptake of advanced imaging technologies.

The market size for non-cystic fibrosis bronchiectasis is anticipated to experience robust expansion over the next few years. It is projected to reach $4.92 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.7%. The expected growth during this period can be attributed to factors such as the increasing incidence of chronic respiratory conditions, the growing embrace of AI and precision medicine, the expansion of home healthcare and telemedicine, innovations in minimally invasive treatments, and the development of healthcare infrastructure in developing markets. Significant trends for the forecast period include the rising adoption of personalized treatment methods, the increasing implementation of remote patient monitoring and telehealth services, the growing application of AI-powered diagnostic tools, the expanding deployment of connected health devices and smart lungs monitoring, and the progressing integration of data-driven clinical decision support systems.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17209&type=smp

What Primary Drivers Are Shaping The Development Of The Non-Cystic Fibrosis Bronchiectasis Market?

The increasing occurrence of respiratory conditions is projected to stimulate expansion in the non-cystic fibrosis bronchiectasis market in the foreseeable future. These ailments involve various disorders impacting the lungs and the entire respiratory system, thereby hindering normal breathing and overall respiratory performance. This upward trend in respiratory disease prevalence largely stems from escalating environmental contamination, encompassing both external pollutants and internal irritants like tobacco smoke. The growing incidence of respiratory infections creates avenues for enhancing the comprehension, detection, and treatment of non-cystic fibrosis bronchiectasis via focused initiatives and public health endeavors. As an illustration, a report released in June 2023 by the Office for Health Improvement and Disparities, a UK-based governmental body, indicated that England recorded 4,622 notifications for scarlet fever Group A Streptococcus bacteria between week 37 and week 46 during the 2022-2023 season, with 851 of these notifications occurring in week 46 alone. This figure significantly surpasses the average of 1,294 notifications (with a range of 258 to 2,008) observed for the identical period (weeks 37 to week 46) throughout the previous five years. Consequently, the increasing occurrence of respiratory illnesses will fuel the expansion of the non-cystic fibrosis bronchiectasis market.

What Segmentation Levels Are Considered In The Non-Cystic Fibrosis Bronchiectasis Market?

The non-cystic fibrosis bronchiectasis market covered in this report is segmented –

1) By Diagnosis: Computed Tomography (CT) Scan, Bronchoscopy, Chest X Ray, Lung Function, Sputum Culture Test, Blood Tests, Other Diagnosis Types

2) By Treatment: Surgery, Physiotherapy, Vaccination, Airway Pharmacotherapy, Antibiotics, Other Treatments

3) By End Use: Hospitals And Clinics, Ambulatory Care Centers, Other End Uses

Subsegments:

1) By Computed Tomography (CT) Scan: High-Resolution CT (HRCT), Standard CT

2) By Bronchoscopy: Flexible Bronchoscopy, Rigid Bronchoscopy

3) By Chest X-Ray: Standard Chest X-Ray, Digital Chest X-Ray

4) By Lung Function: Spirometry, Peak Flow Measurement

5) By Sputum Culture Test: Bacterial Culture, Fungal Culture, Viral Culture

6) By Blood Tests: Complete Blood Count (CBC), C-Reactive Protein (CRP), Immunoglobulin Levels

7) By Other Diagnosis Types: Sweat Test, Genetic Testing, Exhaled Nitric Oxide Test

What Key Developments And Trends Are Impacting The Non-Cystic Fibrosis Bronchiectasis Market?

Leading companies in the non-cystic fibrosis bronchiectasis (NCFB) market are concentrating on developing advanced solutions, such as novel neutrophil elastase–regulating pharmacologic interventions, to enhance the protease–antiprotease balance, lessen chronic tissue damage, and support ongoing management of airway remodeling. A novel neutrophil elastase–regulating pharmacologic intervention for chronic airway inflammation describes a targeted therapeutic approach designed to moderate excessive neutrophil elastase activity, which is a fundamental driver of airway injury and persistent inflammation in NCFB. For example, in November 2025, Insmed, a US-based biopharmaceutical company, obtained European Commission approval for BRINSUPRI (brensocatib), a first-in-class, once-daily oral DPP1 inhibitor. The 25 mg formulation demonstrated a 19.4% reduction in annual exacerbation rate compared to placebo in the Phase 3 ASPEN trial, extended the time to the first exacerbation, and resulted in a higher proportion of patients remaining exacerbation-free. Moreover, it significantly mitigated the decline in lung function (FEV₁) at week 52 and displayed a favorable safety profile, with commonly reported adverse effects including headache, hyperkeratosis, dermatitis, rash, upper respiratory tract infections, and dry skin.

Which Leading Firms Are Contributing To The Growth Of The Non-Cystic Fibrosis Bronchiectasis Market?

Major companies operating in the non-cystic fibrosis bronchiectasis market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Dr Reddys Laboratories Ltd., Chiesi Farmaceutici SpA, Lupin Limited, Zambon Company SpA, Sunovion Pharmaceuticals Inc., Insmed Incorporated, Armata Pharmaceuticals Inc., Renovion Inc., SolAeroMed Inc., CSL Behring, Haisco Pharmaceutical Group Co Ltd., NovaBiotics Ltd., Synspira Therapeutics, Parion Sciences, Regeneron Pharmaceuticals Inc., Gilead Sciences Inc., Infex Therapeutics

Read the full non-cystic fibrosis bronchiectasis market report here:

https://www.thebusinessresearchcompany.com/report/non-cystic-fibrosis-bronchiectasis-global-market-report

How Does The Non-Cystic Fibrosis Bronchiectasis Market Perform Across Major Global Regions?

North America was the largest region in the non-cystic fibrosis bronchiectasis market in 2025. The regions covered in the non-cystic fibrosis bronchiectasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Non-Cystic Fibrosis Bronchiectasis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=17209&type=smp

Browse Through More Reports Similar to the Global Non-Cystic Fibrosis Bronchiectasis Market 2026, By The Business Research Company

Body Fat Reduction Global Market Report

https://www.thebusinessresearchcompany.com/report/body-fat-reduction-global-market-report

Fat Replacers Global Market Report

https://www.thebusinessresearchcompany.com/report/fat-replacers-global-market-report

Lung Cancer Diagnostic And Screening Global Market Report

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795